The treatment strategies for AD have focused on decreasing the load of β-amyloid by inhibition of β-/γ-secretases and Aβ oligomerization; activation of proteases, α-secretase, and immunotherapy (Auld et al., 2002; Citron, 2010; Götz et al., 2012). This evidence concerns the gene PPIB and Alzheimer disease.